Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has reported E.P.S. of $-1.39 for its first fiscal quarter (ending December 31) versus $-1.24 for the same period a year ago. This performance was $-0.67 short of the consensus estimate of $-0.72. For the latest four quarters through December 31, E.P.S. were $-5.16 compared to $-2.76 a year ago.
Recent Price Action
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) stock closed at $19.92 on 2/10/25 after a modest decline of -1.6%. However, trading volume in this decline was below average at 75% of normal. The stock is unchanged during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Arrowhead Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Arrowhead Pharmaceuticals has a poor Power Rating of 25 and a very low Appreciation Score of 2, leading to the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment